small soluble fragments. Urokinase (UK) and streptokinase (SK) are plasminogen activators that convert plasminogen to plasmin. These activators are presently available as thrombolytic agents. However, they have little specific affinity for fibrin and, therefore, can activate circulating and fibrinbound plasminogen relatively indiscriminately.1) Accordingly, when UK or SK is administered, the plasmin in circulating blood will initially be inactivated very rapidly by alpha2-plasmin inhibitor2),7) (alpha2-PI), alphamacroglobulin3) and antithrombin III, 2) and will lose its2) thrombolytic2) efficacy. Once the capacity of these inhibitors becomes exhausted, residual plasmin can degrade several plasma proteins (fibrinogen, coagulant factors V and VIII), which may cause serious bleeding. Moreover, exhaustion of circulating plasminogen results in less effective thrombolysis.
This probably explains why thrombolytic therapy with UK or SK has only limited efficacy and may be associated with serious side effects.4) In an attempt to obtain safer and more effective thrombolytic therapy, we have developed an autologous plasmin (AP)5) solution and evaluated its physiological efficacy in vivo. Thrombolytic effects of the AP solution: In vivo experiments of thrombolytic observation with an ultrasound flow meter:
METHODS

Preparation
Twenty mongrel dogs, weighing 10-14kg, were anesthetized by intravenous injection of sodium pentobarbital (30mg/kg).
After endotracheal intubation, positive pressure respiration (end-expiratoric pressure of 2cm H2O) was instituted with an animal respirator (Harvard Apparatus Co., Natick, MA, USA). The femoral artery was narrowed to 1mm in diameter and an autologous fibrin clot (gel prepared by the addition of 0.2ml, 1/14 mole CaCl2 to 2ml autologous plasma) was placed at the site of stenosis via a polyethylene catheter. Thereafter, either AP solution (n=8), UK solution (n=6) or 0.9% saline (n=6) was selectively infused for 3min via a balloon tip catheter located proximal to the experimental embolus. Two minutes prior to the initiation of the injection, a temporary flow obstruction was made by inflation of the balloon-tip catheter to prevent the compound effects of circulating alpha2,-PI.7) The balloon was kept inflated for 5min. To evaluate2) the thrombolytic effect, the velocity of blood in the femoral artery was measured for 60min with an extravascular ultrasound flow meter8) (equipped with 4MHz pencil probe, Diagnostic Electronics, Inc., USA). The probe was placed and moved for scanning from the 5cm proximal portion to the site of the stenosis (Fig.2 ). ference (p<0.01) in the thrombolytic effect between the AP solution and UK solution was obtained from 15min after infusion (Fig.6) , although the complete or partial reperfusion rates between the AP solution and UK solution were not significantly different. addition, the plasmin activity in this type of preparation was stable for 90min at room temperature. The stability of the solutions prepared with at least 6,000IU/ml UK indicates that plasma plasminogen, the plasminogen-UK reaction and released plasmin are not appreciably inhibited in the preparation.
In vivo experiments have indicated that the UK solution had less thrombolytic efficacy than the AP solution. However, the experimental conditions may not be representative of clinical conditions. For example, the homogeneous fibrin clot that was used in the experiments lacked blood cell components of endogenous thrombi such as platelets, red or white blood cells. Moreover, the access of circulating plasminogen to the clot was impeded by balloon inflation or ligation. Thus, it is possible that the thrombolytic efficacy of the AP solution can be attributed to experimental conditions that maximized the adsorption of activated plasmin onto the fibrin clot. Several attempts have been made to increase the affinity of UK and SK for fibrin. One approach has relied upon prior administration of Lysplasminogen,11) which had higher affinity than Glu-plasminogen.
A second approach is based upon the removal of alpha2-PI by prior infusion of plasmin,12) dextran or orthothymotic acid. However, none of these methods have gained general acceptance.
Moreover, the three most promising approaches towards fibrin-specific thrombolysis have been the development of stable acyl derivatives of SK-plasminogen complex (UPSAC),13) the isolation of human tissue-plasminogen activator (T-PA), 14) and the isolation of a single-chain form of UK (pro UK).15) Some of these agents have been administered in practice. For the patients with acute myocardial infarction within 6 hours from the onset of symptoms, the recanalization rates associated with intravenous application of these drugs are considerably higher than rates achieved by intravenous infusion of SK. However, significant systemic bleeding (estimated as blood loss of 250ml) involving the gastro-intestinal tract (5%), genito-urinal tract (4%), retroperitoneal (1%) or intracranial sites (1.3%), has been reported after intravenous application of T-PA (100-150mg).16) Accordingly, additional trials will be necessary to assess these thrombolytic agents for side effects.
Intravenous plasmin therapy was also reported by Cliffton17) and Ruegsegger18) in the 1950's; however, it could not be widely applied because the plasmin itself had antigenicity and was immediately inhibited by alpha2,-PI.
In this study, we found that the AP solution prepared from autologous plasma had no antigenicity and maintained high plasmin activity for 90min after preparation. Consequently, this plasmin solution was safer and had more thrombolytic efficacy than UK when directly infused near the fibrin 
